A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

NCT02156492 | Completed Phase 1 Results

• 2 other identifiers: 14467I1V-MC-EIAM
• Study Type: interventional
• Target: 62
• Locations: 1 country
• Sites: 1

Brief Summary

The main purpose of this study is to investigate how the body responds to evacetrapib and to evaluate the safety and the effect of evacetrapib, alone and in combination with selected statins, in healthy Chinese participants. The study has 2 parts. Part one will last up to 4 weeks and part two will last up to 5 weeks, not including screening. Participants may only enroll in one part.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (6)

• Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib

  Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.

  Part 1: Day 1 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours Postdose

• PK: Maximum Concentration (Cmax) of Evacetrapib

  Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.

  Part 1: Day 1 and Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours Postdose

• PK: Time to Maximum Concentration (Tmax) of Evacetrapib

  Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.

  Part 1: Day 1 Predose on Day 1 or Day 14 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours postdose. Part 2: Predose on Day 14 at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose.

• PK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin

  Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).

  Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose

• PK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin

  Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.

  Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose.

• PK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin

  Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.

  Part 2: Predose on Day 14 and 22 and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose.

Secondary Outcomes (1)

• Effect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)

  Single Dose Day 2 and Multiple Dose Day 22

Study Arms (6)

Evacetrapib Single

EXPERIMENTAL

Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.

Drug: Evacetrapib

Evacetrapib Multiple

EXPERIMENTAL

Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.

Drug: Evacetrapib

Simvastatin

ACTIVE COMPARATOR

Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.

Drug: Simvastatin

Evacetrapib and Simvastatin

EXPERIMENTAL

Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.

Drug: Evacetrapib; Drug: Simvastatin

Atorvastatin

ACTIVE COMPARATOR

Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.

Drug: Atorvastatin

Evacetrapib and Atorvastatin

EXPERIMENTAL

Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.

Drug: Evacetrapib; Drug: Atorvastatin

Interventions

Evacetrapib DRUG

Administered orally.

Also known as: LY2484595

Evacetrapib Multiple; Evacetrapib Single; Evacetrapib and Atorvastatin; Evacetrapib and Simvastatin

Simvastatin DRUG

Administered orally.

Evacetrapib and Simvastatin; Simvastatin

Atorvastatin DRUG

Administered orally.

Atorvastatin; Evacetrapib and Atorvastatin

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Are native Chinese and living in China.
• Are overtly healthy males or females as determined by medical history and physical examination.
• Female participants:
• Women not of child-bearing potential
• Women of child-bearing potential must correctly use 2 forms of reliable contraception to avoid getting pregnant during the study and for 3 months after the study is completed.
• Body Mass Index: 19.0 to 24.0 kilogram per square meter (kg/m\^2)
• BP and pulse rate at both supine and standing positions of approximately a systolic BP ≤ 140 millimeter of mercury (mm Hg), and diastolic BP ≤ 90 mm Hg
• Participants with untreated hypercholesterolemia may be included if not on an herbal or other traditional Chinese medicines (TCM)
• Have no known liver disease
• Have given written informed consent

You may not qualify if:

• Are currently enrolled in a clinical trial involving an investigational product (IP) or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
• Have known allergies to evacetrapib, simvastatin, or atorvastatin, related compounds or any components of the formulation
• Have previously completed or withdrawn from this study or any other study investigating evacetrapib, and have previously received the IP within 3 months.
• Have a history within the last year or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
• Show evidence of significant active neuropsychiatric disease.
• Regularly use known drugs of abuse
• Are women with a positive pregnancy test or women who are lactating.
• Have used or intend to use over-the-counter or prescription medications (including vitamins/mineral supplements) or TCM 14 days prior to the first dose and during the study.
• Hormonal contraceptives are permitted.
• Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of organic anion transporting polypeptide 1B1 (OATP1B1), or of any other transporters involved in simvastatin or atorvastatin disposition, or of any drugs or substances that are known to be strong inducers or inhibitors of cytochrome P450 3A (CYP3A) within 30 days prior to the first dose and throughout the study.
• Donated blood of \>400 mL within the last month.
• Drink alcoholic beverages with intake that exceeds 28 units per week (males) and 21 units per week (females), or are unwilling to stop alcohol consumption 48 hours prior to dosing until discharge from the clinical research unit (CRU) (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
• Are unwilling to comply with the dietary requirements/restrictions during the study

Sponsors & Collaborators

• Eli Lilly and Company: lead

Study Sites (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Beijing, 100034, China

Location

MeSH Terms

Interventions

evacetrapib; Simvastatin; Atorvastatin

Intervention Hierarchy (Ancestors)

Lovastatin; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Pyrroles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heptanoic Acids; Fatty Acids; Lipids

Results Point of Contact

• Title: Chief Medical Officer
• Organization: Eli Lilly and Company

800-545-5979

Study Officials

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

  Eli Lilly and Company

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 28, 2014
• First Posted: June 5, 2014
• Study Start: June 1, 2014
• Primary Completion: December 1, 2014
• Study Completion: December 1, 2014
• Last Updated: October 10, 2018
• Results First Posted: October 10, 2018

Record last verified: 2018-02

Locations

CN (1)